|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RUNDC3B |
Gene summary for RUNDC3B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RUNDC3B | Gene ID | 154661 |
| Gene name | RUN domain containing 3B | |
| Gene Alias | RPIB9 | |
| Cytomap | 7q21.12 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q96NL0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 154661 | RUNDC3B | AEH-subject5 | Human | Endometrium | AEH | 4.62e-05 | 2.06e-01 | -0.2953 |
| 154661 | RUNDC3B | EEC-subject4 | Human | Endometrium | EEC | 8.25e-04 | 1.51e-01 | -0.2571 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RUNDC3B | SNV | Missense_Mutation | c.739N>A | p.Glu247Lys | p.E247K | Q96NL0 | protein_coding | deleterious(0.04) | possibly_damaging(0.866) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| RUNDC3B | SNV | Missense_Mutation | novel | c.1343N>A | p.Ser448Tyr | p.S448Y | Q96NL0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RUNDC3B | SNV | Missense_Mutation | novel | c.1103N>T | p.Ala368Val | p.A368V | Q96NL0 | protein_coding | tolerated(0.1) | possibly_damaging(0.694) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| RUNDC3B | SNV | Missense_Mutation | c.515T>G | p.Phe172Cys | p.F172C | Q96NL0 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RUNDC3B | SNV | Missense_Mutation | c.671N>T | p.Tyr224Phe | p.Y224F | Q96NL0 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RUNDC3B | SNV | Missense_Mutation | novel | c.445G>T | p.Ala149Ser | p.A149S | Q96NL0 | protein_coding | tolerated(0.12) | probably_damaging(0.99) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| RUNDC3B | SNV | Missense_Mutation | rs768512540 | c.323G>A | p.Arg108His | p.R108H | Q96NL0 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RUNDC3B | SNV | Missense_Mutation | novel | c.601T>C | p.Phe201Leu | p.F201L | Q96NL0 | protein_coding | tolerated(0.12) | possibly_damaging(0.656) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RUNDC3B | SNV | Missense_Mutation | c.1220C>T | p.Pro407Leu | p.P407L | Q96NL0 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD | |
| RUNDC3B | SNV | Missense_Mutation | novel | c.1288N>G | p.Thr430Ala | p.T430A | Q96NL0 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |